Elisrasib, a next-generation KRAS G12C inhibitor, showed promising clinical benefit in advanced lung cancer patients at AACR 2026.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer
Next-Generation KRAS G12C Inhibitor Drug type
Advanced NSCLC With KRAS G12C Mutations Patient population
Promising Response Rates After Prior Therapies Clinical outcome